University of Pittsburgh researchers reported promising results in mice with a potential "gene therapy" for Gaucher's disease that eventually may replace Ceredase, a Genzyme Corp. drug whose high cost has sparked controversy.
The study indicated it would be possible to transfer a gene into certain cells of people with the disease that would permanently correct a genetic defect underlying their disorder. The potential treatment, however, is at least several years away from widespread use in patients, and its development may face economic stumbling blocks.